We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Mark Swain

Mark G. Swain MD, MSc, FRCPC, FAASLD, FCAHS

Cal Wenzel Family Foundation Chair in Hepatology, Professor of Medicine, and Head, Division of Gastroenterology and Hepatology, University of Calgary; Section Head, Section of Gastroenterology and Hepatology, Calgary Zone, Alberta Health Services, Calgary, Alberta, Canada

Dr. Mark Swain is Professor of Medicine and Head of the Division of Gastroenterology and Hepatology at the University of Calgary, Alberta, Canada. He currently holds the Cal Wenzel Family Foundation Chair in Hepatology. Dr. Swain is a clinician-scientist with a basic science research interest focused on how liver diseases causes symptoms such as fatigue. His clinical interests are focused in the areas of quality improvement and wait time reduction strategies, and his clinical research interests involve studying fatty liver disease (NAFLD), primary biliary cirrhosis, autoimmune hepatitis and eradicating hepatitis C.

Disclosures

Dr. Swain reports the following:
  • Advisory board: Gilead, Intercept, Novartis
  • Speaker: Gilead, Intercept, Abbott
  • Clinical trial or research support: Gilead, BMS, CymaBay, Intercept, Genfit, Pfizer, Novartis, Astra Zeneca, GSK, Celgene, Novo Nordisk, Axcella Health Inc., Merck, Galectin Therapeutics